peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Genovis AB files complaint for patent infringement by Promega Inc.

11 Nov 2014, 08:41
Regulatory information
Genovis AB, in which Hansa Medical strategically holds ten per cent of the shares, has filed a complaint for patent infringement by Promega in the United States of America regarding one of Promega Inc’s products which concerns Genovis’ product FabRICATOR, originally developed using technology licensed from Hansa Medical.

Genovis AB develops and sells unique enzymes in innovative formats facilitating quality control and development of antibody-based pharmaceuticals. Genovis’ enzyme products are partially based on enzymes originally developed and patented by Hansa Medical. Since 2012, Hansa Medical controls a strategic investment in Genovis mounting to 2 177 065 shares equivalent to ten per cent of the company. The patent infringement affect Genovis’ exclusive rights for laboratory reagent use of the protein tool FabRICATOR but has no bearing on Hansa Medical’s therapeutic line of business involving similar enzymes.

”We follow this case as it unfolds, keeping us informed due to our strategic holding in Genovis. The patent infringement concern Genovis’ specific business area but does not affect ours”, comments Emanuel Björne, CEO, Hansa Medical AB

More on Genovis AB
Genovis AB is a biotechnology company developing enzyme-based protein tools facilitating development and quality control of antibody-based drugs. Genovis AB is listed on NASDAQ OMX First North and is traded under the ticker name GENO.

More on FabRICATOR
Genovis’ product FabRICATOR was originally developed using Hansa Medical’s enzyme IdeS specifically for laboratory applications. Hansa Medical controls all legal rights as to therapeutic applications of the enzyme.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory conditions. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.